Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycob...
Q2 2026
Aug 6, 2026
Q1 2026
May 7, 2026
FY 2025
Feb 19, 2026
Q4 2025
Q3 2025
Oct 30, 2025